ADC Therapeutics (ADCT) Operating Leases (2019 - 2026)

ADC Therapeutics (ADCT) has reported Operating Leases for 8 consecutive years, with $991000.0 the latest figure, recorded in Q1 2026.

• Quarterly Operating Leases fell 87.47% year-over-year to $991000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $991000.0 (down 87.47% YoY) and the FY2025 annual result came in at $1.0 million, down 87.07% from the prior year.
• Operating Leases slipped to $991000.0 in Q1 2026 per ADCT's latest filing, from $1.0 million in the prior quarter.
• Over the last five years, Operating Leases for ADCT reached as high as $12.4 million in Q1 2023 and fell as low as $991000.0 in Q1 2026.
• A 5-year average of $7.4 million and a median of $7.9 million in 2025 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2023 — Operating Leases surged 79.65% — and 2026, when it plunged 87.47%.
• Year by year, Operating Leases stood at $6.6 million in 2022, then surged by 55.09% to $10.2 million in 2023, then decreased by 21.46% to $8.0 million in 2024, then tumbled by 87.07% to $1.0 million in 2025, then fell by 4.16% to $991000.0 in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $991000.0, $1.0 million, and $2.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.